… cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic
non–small-cell lung cancer (… of gemcitabine plus cisplatin compared with cisplatin alone in …

… IV NSCLC received gemcitabine 1250 mg/m 2 (days 1 and 8) plus cisplatin 80 mg… gemcitabine
plus cisplatin therapy were randomized (2:1 fashion) to receive maintenance gemcitabine …

… day-8 dose of gemcitabine because of bone marrow … cisplatin 80 mg/m 2 , gemcitabine
1000 mg/m 2 or cisplatin 60 mg/m 2 , gemcitabine 1000 mg/m 2 ; carboplatin AUC 5, gemcitabine …

… gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced
non–small-cell lung cancer (… were randomized to receive either gemcitabine 1,250 mg/m 2 …

… 2′-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin,
CDDP) are active agents against ovarian cancer and non-small-cell lung cancer (NSCLC). …

… , and the toxicity of gemcitabine/cisplatin (GP) and gemcitabine/… lung cancer (NSCLC).
Methods: Patients were randomized to GP (gemcitabine 1200 mg/m 2 , days 1 and 8 plus cisplatin …

… gemcitabine 1200 mg/m 2 days 1 and 8. Patients in experimental arm received cisplatin 60
mg/m 2 day 1 plus gemcitabine … gemcitabine and 5.9 months with cisplatin plus gemcitabine (…

… the GC regimen with an etoposide plus cisplatin combination (EP), the … cisplatin, and the
Italian Lung Cancer Project (ILCP) compared it with a mitomycin plus ifosfamide plus cisplatin …

… of cisplatin and gemcitabine on toxicity and drug delivery in phase II studies of non-small cell
lung cancer. … had standard entry criteria for advanced non-small cell lung cancer. Whereas …

… Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-smallcell lung
cancer: A randomized trial by the Spanish lung cancer … World Conference of Lung Cancer, 10-…